Haplo ever after: haplo PTCy for children.
作者信息
Talano Julie-An, Broglie Larisa
机构信息
Department of Pediatric Hematology Oncology and Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI.
出版信息
Blood Adv. 2023 Sep 26;7(18):5637-5638. doi: 10.1182/bloodadvances.2023010755.
Abstract
摘要
相似文献
1
Haplo ever after: haplo PTCy for children.
Blood Adv. 2023 Sep 26;7(18):5637-5638. doi: 10.1182/bloodadvances.2023010755.
2
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
Transplant Cell Ther. 2022 Oct;28(10):681-693. doi: 10.1016/j.jtct.2022.07.013. Epub 2022 Jul 16.
3
Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.
Bone Marrow Transplant. 2022 Nov;57(11):1681-1688. doi: 10.1038/s41409-022-01770-y. Epub 2022 Aug 20.
4
Effect of Donor NKG2D Polymorphism on Relapse after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.
Transplant Cell Ther. 2022 Jan;28(1):20.e1-20.e10. doi: 10.1016/j.jtct.2021.09.019. Epub 2021 Oct 1.
5
Increased Infections and Delayed CD4 T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation.
Transplant Cell Ther. 2021 Nov;27(11):940-948. doi: 10.1016/j.jtct.2021.07.023. Epub 2021 Jul 28.
6
Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML.
Bone Marrow Transplant. 2017 Aug;52(8):1138-1143. doi: 10.1038/bmt.2017.36. Epub 2017 Mar 27.
7
Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia.
Transplant Cell Ther. 2023 Jun;29(6):365.e1-365.e11. doi: 10.1016/j.jtct.2023.03.001. Epub 2023 Mar 6.
8
Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Transplant Cell Ther. 2022 Sep;28(9):587.e1-587.e7. doi: 10.1016/j.jtct.2022.06.006. Epub 2022 Jun 14.
9
Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation.
Adv Hematol. 2015;2015:431923. doi: 10.1155/2015/431923. Epub 2015 Dec 2.
10
Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Transplant Cell Ther. 2022 Mar;28(3):158.e1-158.e9. doi: 10.1016/j.jtct.2021.11.009. Epub 2021 Nov 25.
本文引用的文献
1
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.
Blood Adv. 2023 Sep 26;7(18):5639-5648. doi: 10.1182/bloodadvances.2023010281.
2
Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia.
Transplant Cell Ther. 2021 May;27(5):424.e1-424.e9. doi: 10.1016/j.jtct.2021.01.016. Epub 2021 Jan 21.
3
Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective.
J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e1033-e1036. doi: 10.1097/MPH.0000000000002030.
4
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.
Blood Adv. 2020 Aug 25;4(16):3913-3925. doi: 10.1182/bloodadvances.2020001648.
5
T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies.
Front Pediatr. 2020 Jun 9;8:282. doi: 10.3389/fped.2020.00282. eCollection 2020.
6
Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH).
Am J Hematol. 2020 Jan;95(1):28-37. doi: 10.1002/ajh.25661. Epub 2019 Nov 5.
7
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.
Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.
8
Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions.
Biol Blood Marrow Transplant. 2016 Oct;22(10):1867-1873. doi: 10.1016/j.bbmt.2016.07.016. Epub 2016 Jul 25.
9
Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study.
Biol Blood Marrow Transplant. 2016 May;22(5):902-9. doi: 10.1016/j.bbmt.2016.02.002. Epub 2016 Feb 6.
10
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.
Biol Blood Marrow Transplant. 2002;8(7):377-86. doi: 10.1053/bbmt.2002.v8.pm12171484.
Zotero 插件